Bio-Rad Laboratories, Inc. Class A Common Stock vs Rush Street Interactive Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $353.89 (market cap $9.43B), while Rush Street Interactive Inc trades at $24.65 (market cap $2.91B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.2× Rush Street Interactive Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals.
| BIO | RSI | |
|---|---|---|
Market Cap | $9.43B | $2.91B |
Sector | Health | Technology |
52-Week High | $356.25 | $34.52 |
52-Week Low | $241.71 | $15.89 |
Enterprise Value | $9.18B | $2.57B |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Rush Street Interactive (RSI) trades at $25.08, up 1.46% today, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Despite a high P/E ratio of 81.13, profitability metrics like a 20.72% ROE and recent earnings beats signal operational strength. Key resistance sits at $26, with support near $24.
The outlook is positive driven by revenue growth and market expansion, but high valuation and mixed technicals pose risks. Analyst consensus is bullish with a $34.75 price target, though regulatory pressures in the gaming sector remain a concern. The stock offers growth potential but requires monitoring of execution and market sentiment.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →